% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Schurig:138111,
author = {Schurig, Katja and Zieris, Andrea and Hermann, Andreas and
Freudenberg, Uwe and Heidel, Sabine and Grimmer, Milauscha
and Storch, Alexander and Werner, Carsten},
title = {{N}eurotropic growth factors and glycosaminoglycan based
matrices to induce dopaminergic tissue formation.},
journal = {Biomaterials},
volume = {67},
issn = {0142-9612},
address = {Amsterdam [u.a.]},
publisher = {Elsevier Science},
reportid = {DZNE-2020-04433},
pages = {205-213},
year = {2015},
abstract = {Current cell replacement therapies in Parkinson's disease
(PD) are limited by low survival of transplanted cell and
lacking regeneration of neuronal circuitries. Therefore,
bioartificial cell carriers and growth/differentiation
factors are applied to improve the integration of
transplants and maximize newly generated and/or residual
dopaminergic function. In this work, biohybrid poly(ethylene
glycol) (starPEG)-heparin hydrogels releasing fibroblast
growth factor 2 (FGF-2) and glial-derived neurotrophic
factor (GDNF) were used to trigger dopaminergic tissue
formation by primary murine midbrain cells in vitro.
Matrix-delivered FGF-2 enhanced cell viability while release
of GDNF had a pro-neuronal/dopaminergic effect. Combined
delivery of both factors from the glycosaminoglycan-based
matrices resulted in a tremendous improvement in survival
and maturation capacity of dopaminergic neurons as obvious
from tyrosine hydroxylase expression and neurite outgrowth.
The reported data demonstrate that glycosaminoglycan-based
hydrogels can facilitate the administration of neurotrophic
factors and are therefore instrumental in potential future
treatments of PD.},
keywords = {Animals / Cell Differentiation: drug effects / Cell
Survival: drug effects / Cells, Cultured / Dopaminergic
Neurons: cytology / Dopaminergic Neurons: drug effects /
Drug Liberation / Female / Fetus: cytology / Fibroblast
Growth Factor 2: pharmacology / Glial Cell Line-Derived
Neurotrophic Factor: pharmacology / Glycosaminoglycans:
pharmacology / Heparin: chemistry / Hydrogels: chemical
synthesis / Mesencephalon: cytology / Mice, Inbred C57BL /
Nerve Growth Factors: pharmacology / Neural Stem Cells:
cytology / Neural Stem Cells: drug effects / Neurites: drug
effects / Neurites: metabolism / Neuroglia: cytology /
Neuroglia: drug effects / Polyethylene Glycols: chemical
synthesis / Tissue Engineering: methods / Glial Cell
Line-Derived Neurotrophic Factor (NLM Chemicals) /
Glycosaminoglycans (NLM Chemicals) / Hydrogels (NLM
Chemicals) / Nerve Growth Factors (NLM Chemicals) /
Fibroblast Growth Factor 2 (NLM Chemicals) / Polyethylene
Glycols (NLM Chemicals) / Heparin (NLM Chemicals)},
cin = {AG Storch / AG Teipel},
ddc = {570},
cid = {I:(DE-2719)5000014 / I:(DE-2719)1510100},
pnm = {344 - Clinical and Health Care Research (POF3-344)},
pid = {G:(DE-HGF)POF3-344},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:26222283},
doi = {10.1016/j.biomaterials.2015.07.029},
url = {https://pub.dzne.de/record/138111},
}